MorphoSys AG ADR Performance
The company secures a Beta (Market Risk) of -0.13, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning MorphoSys are expected to decrease at a much lower rate. During the bear market, MorphoSys is likely to outperform the market. MorphoSys AG ADR right now secures a risk of 0.0%. Please verify MorphoSys AG ADR variance and potential upside , to decide if MorphoSys AG ADR will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MorphoSys AG ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, MorphoSys is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 402.4 M |
MorphoSys |
MorphoSys Relative Risk vs. Return Landscape
If you would invest (100.00) in MorphoSys AG ADR on September 18, 2024 and sell it today you would earn a total of 100.00 from holding MorphoSys AG ADR or generate -100.0% return on investment over 90 days. MorphoSys AG ADR is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than MorphoSys, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
MorphoSys Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MorphoSys' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MorphoSys AG ADR, and traders can use it to determine the average amount a MorphoSys' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MOR |
Based on monthly moving average MorphoSys is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MorphoSys by adding MorphoSys to a well-diversified portfolio.
MorphoSys Fundamentals Growth
MorphoSys Stock prices reflect investors' perceptions of the future prospects and financial health of MorphoSys, and MorphoSys fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MorphoSys Stock performance.
| Return On Equity | -1.84 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (1.91) % | |||
| Operating Margin | (9.60) % | |||
| Current Valuation | 2.68 B | |||
| Shares Outstanding | 150.65 M | |||
| Price To Earning | 4.52 X | |||
| Price To Book | 53.81 X | |||
| Price To Sales | 11.83 X | |||
| Revenue | 238.28 M | |||
| EBITDA | (97.74 M) | |||
| Cash And Equivalents | 726.83 M | |||
| Cash Per Share | 5.32 X | |||
| Total Debt | 635.93 M | |||
| Debt To Equity | 2.31 % | |||
| Book Value Per Share | (6.96) X | |||
| Cash Flow From Operations | (295.84 M) | |||
| Earnings Per Share | (1.50) X | |||
| Total Asset | 2.03 B | |||
| Retained Earnings | (1.01 B) | |||
| Current Asset | 386.7 M | |||
| Current Liabilities | 48.64 M | |||
About MorphoSys Performance
Assessing MorphoSys' fundamental ratios provides investors with valuable insights into MorphoSys' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MorphoSys is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. The company was founded in 1992 and is headquartered in Planegg, Germany. Morphosys operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 648 people.Things to note about MorphoSys AG ADR performance evaluation
Checking the ongoing alerts about MorphoSys for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MorphoSys AG ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MorphoSys AG ADR is not yet fully synchronised with the market data | |
| MorphoSys AG ADR has some characteristics of a very speculative penny stock | |
| MorphoSys AG ADR has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 238.28 M. Reported Net Loss for the year was (189.73 M) with profit before taxes, overhead, and interest of 229.65 M. | |
| MorphoSys AG ADR has about 726.83 M in cash with (295.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32. |
- Analyzing MorphoSys' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MorphoSys' stock is overvalued or undervalued compared to its peers.
- Examining MorphoSys' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MorphoSys' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MorphoSys' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MorphoSys' stock. These opinions can provide insight into MorphoSys' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |